微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 26.52% | -36.09% | -23.78% | 122/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 34.8% | -29.53% | 0.89% | 105/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 34.49% | -30.88% | -11.11% | 105/157 | -2.2% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 38.8% | -23.88% | -6.5% | 94/157 | 14.83% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 41.5% | -15.55% | -15.95% | 89/157 | 31.96% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 49.37% | 2.57% | -1.04% | 79/157 | 51.88% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 49.89% | 6.06% | -2.12% | 79/157 | 22.51% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 50.97% | 5.82% | 3.73% | 77/157 | 33.12% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 49.14% | 3.14% | 2.09% | 80/157 | 51.76% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 48.14% | -9.77% | 2.33% | 81/157 | 51.61% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 47.04% | -6.95% | -2.34% | 86/157 | 32.47% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 48.17% | -4.73% | 1.1% | 83/157 | 38.42% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 47.65% | -4.75% | -10.69% | 81/157 | 52.97% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 53.35% | -2.35% | 5.53% | 76/157 | 53.83% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 50.55% | -1.7% | -0.02% | 77/157 | 5.64% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 50.56% | -4.16% | 1.08% | 83/157 | 20.99% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 50.02% | -4.05% | -8.44% | 78/157 | 54.39% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 54.63% | 1.47% | 6.23% | 77/157 | 55.2% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 51.43% | -3.94% | -2.52% | 69/157 | 46.77% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 52.76% | 4.69% | 1.2% | 73/157 | 47.23% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 52.13% | 8.97% | -3.17% | 67/157 | 54.13% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 53.84% | -10.55% | 0.56% | 74/157 | -148.64% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 53.54% | -14.04% | 6.24% | 63/157 | 56.43% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 50.39% | -24.2% | 5.34% | 69/157 | 54.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 47.84% | -28.03% | -20.52% | 67/157 | 55.17% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 60.19% | -12.26% | -3.36% | 57/157 | -1242.15% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 62.28% | -5.99% | -6.31% | 40/157 | 55.23% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 66.48% | 2.79% | 0.01% | 33/157 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 66.47% | 7.5% | -3.09% | 26/157 | 51.07% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 68.6% | -0.47% | 3.55% | 38/157 | -211.97% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 66.25% | -0.28% | 2.43% | 25/157 | 54.14% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 64.68% | 0.59% | 4.59% | 31/157 | 53.53% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 61.84% | -3.25% | -10.27% | 35/157 | 54.16% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 68.92% | 17.83% | 3.74% | 28/157 | 52.55% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 66.44% | 20.12% | 3.33% | 21/157 | 49.09% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 64.3% | 21.49% | 0.59% | 22/157 | 47.91% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 63.92% | 20.57% | 9.28% | 22/157 | 46.94% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 58.49% | 2.71% | 5.75% | 34/157 | 48.46% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 55.31% | 2.42% | 4.5% | 25/157 | 46.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 52.92% | -2.33% | -0.17% | 31/157 | 46.26% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 53.01% | 1.85% | -6.91% | 23/157 | 43.86% | 微芯生物 | 97.46% | 行业排名> |